Group 1 - The core point of the news is that Beilu Pharmaceutical's stock price has dropped by 5.15%, currently trading at 9.94 yuan per share, with a total market capitalization of 5.595 billion yuan [1] - Beilu Pharmaceutical, established on September 5, 1992, and listed on October 30, 2009, specializes in the production, research, and sales of contrast agents, central nervous system drugs, and hypoglycemic drugs [1] - The revenue composition of Beilu Pharmaceutical includes 63.33% from contrast agents, 22.09% from traditional Chinese medicine, 12.75% from hypoglycemic drugs, and 1.83% from other products [1] Group 2 - Guolian Fund has a significant holding in Beilu Pharmaceutical, with the Guolian Medical Health Mixed A fund (006240) holding 229,100 shares, representing 5.12% of the fund's net value [2] - The Guolian Medical Health Mixed A fund has a total scale of 3.9704 million, with a year-to-date return of 25.72% and a one-year return of 24.07% [2] - The fund manager, Liu Baichuan, has been in position for 227 days, with the fund's total assets amounting to 42.4421 million, achieving a best return of 27.1% during his tenure [3]
北陆药业股价跌5.15%,国联基金旗下1只基金重仓,持有22.91万股浮亏损失12.37万元